Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment
© 2023 John Wiley & Sons Ltd..
BACKGROUND: Patients with chronic hepatitis B (CHB) on nucleos(t)ide analogues (NUCs) often experience renal function decline. Conflicting results regarding the impact of NUC use and renal function have recently been reported.
AIM: To examine longitudinal changes in renal function according to the NUC treatment type compared with untreated patients METHODS: From 2014 to 2022, we retrospectively analysed 10,642 patients with CHB. The primary outcome was chronic kidney disease (CKD) progression, which was defined as a minimum one-stage elevation. We applied propensity score (PS) matching for outcome comparisons.
RESULTS: In the PS-matched cohort of 1996 pairs, the NUC-treated group (7.6/100 person-years [PYs]) had a significantly higher CKD progression risk than the untreated group (4.4/100 PYs), with a hazard ratio (HR) of 1.70 (p < 0.001). The tenofovir disoproxil fumarate (TDF)-treated group (7.9/100 PYs) showed a 1.76-fold increased CKD progression risk compared with the untreated group (4.5/100 PYs) in the PS-matched cohort (p < 0.001). Both the entecavir- and tenofovir alafenamide (TAF)-treated groups showed CKD progression risks comparable to those of the untreated group in the PS-matched cohorts of 755 and 426 pairs, respectively (p = 0.132 and p = 0.120, respectively). No significant CKD progression risk was found between the entecavir- (6.0/100 PYs) and TAF-treated (5.2/100 PYs) groups in the PS-matched cohort of 510 pairs (p = 0.118).
CONCLUSIONS: NUC-treated patients, especially those on TDF, faced a higher CKD progression risk than untreated patients. Entecavir- and TAF-treated patients had comparable CKD progression risks to untreated patients. No difference was observed between entecavir and TAF in the risk of CKD progression.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
---|---|
Enthalten in: |
Alimentary pharmacology & therapeutics - 59(2024), 4 vom: 28. Jan., Seite 515-525 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hong, Hyeyeon [VerfasserIn] |
---|
Links: |
---|
Themen: |
99YXE507IL |
---|
Anmerkungen: |
Date Completed 23.01.2024 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/apt.17819 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365005010 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM365005010 | ||
003 | DE-627 | ||
005 | 20240123231931.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/apt.17819 |2 doi | |
028 | 5 | 2 | |a pubmed24n1268.xml |
035 | |a (DE-627)NLM365005010 | ||
035 | |a (NLM)38009290 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hong, Hyeyeon |e verfasserin |4 aut | |
245 | 1 | 0 | |a Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.01.2024 | ||
500 | |a Date Revised 23.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 John Wiley & Sons Ltd. | ||
520 | |a BACKGROUND: Patients with chronic hepatitis B (CHB) on nucleos(t)ide analogues (NUCs) often experience renal function decline. Conflicting results regarding the impact of NUC use and renal function have recently been reported | ||
520 | |a AIM: To examine longitudinal changes in renal function according to the NUC treatment type compared with untreated patients METHODS: From 2014 to 2022, we retrospectively analysed 10,642 patients with CHB. The primary outcome was chronic kidney disease (CKD) progression, which was defined as a minimum one-stage elevation. We applied propensity score (PS) matching for outcome comparisons | ||
520 | |a RESULTS: In the PS-matched cohort of 1996 pairs, the NUC-treated group (7.6/100 person-years [PYs]) had a significantly higher CKD progression risk than the untreated group (4.4/100 PYs), with a hazard ratio (HR) of 1.70 (p < 0.001). The tenofovir disoproxil fumarate (TDF)-treated group (7.9/100 PYs) showed a 1.76-fold increased CKD progression risk compared with the untreated group (4.5/100 PYs) in the PS-matched cohort (p < 0.001). Both the entecavir- and tenofovir alafenamide (TAF)-treated groups showed CKD progression risks comparable to those of the untreated group in the PS-matched cohorts of 755 and 426 pairs, respectively (p = 0.132 and p = 0.120, respectively). No significant CKD progression risk was found between the entecavir- (6.0/100 PYs) and TAF-treated (5.2/100 PYs) groups in the PS-matched cohort of 510 pairs (p = 0.118) | ||
520 | |a CONCLUSIONS: NUC-treated patients, especially those on TDF, faced a higher CKD progression risk than untreated patients. Entecavir- and TAF-treated patients had comparable CKD progression risks to untreated patients. No difference was observed between entecavir and TAF in the risk of CKD progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a NUC treatment | |
650 | 4 | |a chronic hepatitis B | |
650 | 4 | |a chronic kidney disease | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Tenofovir |2 NLM | |
650 | 7 | |a 99YXE507IL |2 NLM | |
700 | 1 | |a Cho, Minjoo |e verfasserin |4 aut | |
700 | 1 | |a Lim, Chaeyeon |e verfasserin |4 aut | |
700 | 1 | |a Choi, Won-Mook |e verfasserin |4 aut | |
700 | 1 | |a Lee, Danbi |e verfasserin |4 aut | |
700 | 1 | |a Shim, Ju Hyun |e verfasserin |4 aut | |
700 | 1 | |a Kim, Kang Mo |e verfasserin |4 aut | |
700 | 1 | |a Lim, Young-Suk |e verfasserin |4 aut | |
700 | 1 | |a Lee, Han Chu |e verfasserin |4 aut | |
700 | 1 | |a Choi, Jonggi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 59(2024), 4 vom: 28. Jan., Seite 515-525 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
773 | 1 | 8 | |g volume:59 |g year:2024 |g number:4 |g day:28 |g month:01 |g pages:515-525 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17819 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 59 |j 2024 |e 4 |b 28 |c 01 |h 515-525 |